Two global pharmaceutical firms ďż˝ Hilleman Laboratories and Gotovax AB ďż˝ Tuesday joined hands to develop affordable oral cholera vaccine.
�Our partnership with Gotovax AB is carefully aligned to Hilleman Laboratories� core philosophy of addressing unmet health needs of the underprivileged by developing accessible and innovative vaccines which are affordable,� Hilleman Laboratories� chief executive officer Davinder Gill said.
Hilleman Laboratories is a Merck & Co and Wellcome Trust joint venture while Gotovax AB is a bio-pharmaceutical firm.
�There is an urgent need for highly effective and affordable Cholera vaccines both for outbreaks as well as mass vaccination campaigns.
�Cholera is endemic in over 50 countries with estimated mortality of 100,000-120,000 deaths each year and a morbidity of 3.8-4.4 million annual cases attributed to this disease,� he added.
Source: GBC
Disclaimer: Opinions expressed here are those of the writers and do not reflect those of Peacefmonline.com. Peacefmonline.com accepts no responsibility legal or otherwise for their accuracy of content. Please report any inappropriate content to us, and we will evaluate it as a matter of priority. |